Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More – Xconomy
Xconomy |
Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More
Xconomy Meanwhile, plans to replace the Affordable Care Act crept forward, the potential new Medicare/Medicaid chief testified before a congressional committee, and the legal feud over ownership of the gene editing technology CRISPR-Cas9 continued. Let's get … |
